Gene Therapy for Wet AMD

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

December 30, 2027

Conditions
Neovascular Age-related Macular Degeneration
Interventions
GENETIC

FT-003

Administered via intraocular injection.

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Tianjin Medical University Eye Hospital

OTHER

collaborator

Peking Union Medical College Hospital

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Frontera Therapeutics

INDUSTRY

NCT05611424 - Gene Therapy for Wet AMD | Biotech Hunter | Biotech Hunter